Breast Cancer: Influence of Taxanes on Response Assessment with Dynamic Contrast-enhanced MR Imaging

Abstract

The reduction of enhancement observed in breast cancers after T-NACT is, in part, unrelated to their oncologic response. MR imaging-detectable effects of taxanes represent a combination of specific antimitotic and nonspecific antiangiogenic effects. This impacts the accuracy with which dynamic contrast-enhanced MR imaging helps predict complete pathologic response to T-NACT. (©) RSNA, 2015 Online supplemental material is available for this article.

Role of dynamic contrast‐enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER‐positive, HER2‐negative, node‐negative invasive breast cancer

“…Methods used for quantitative measurements of BPE vary across studies . Earlier studies on BPE have mainly used qualitative BPE assessments or an ROI‐based quantitative method by including the most enhancing portion of the breast . Recently, several studies have applied quantitative BPE assessment using fibroglandular tissue segmentation .…”

“…32 Earlier studies on BPE have mainly used qualitative BPE assessments or an ROI-based quantitative method by including the most enhancing portion of the breast. 11,12,[33][34][35] Recently, several studies have applied quantitative BPE assessment using fibroglandular tissue segmentation. 2,[36][37][38] ROI-based quantitative assessment has the advantage of being easy to perform and excludes coexisting benign enhancing breast lesions, but interobserver variability is inevitable.…”

Evaluation of background parenchymal enhancement on breast MRI: a systematic review

“…BPE was described as percentage enhancement rates or a relative percentage enhancement in 11 studies, 22,24,30,32,46,47,[53][54][55]58,59 with the use of both pre-and post-contrast images. There was a wide heterogeneity in the time selection of images obtained after contrast agent injection for relative percentage enhancement or percentage enhancement rate calculation.…”

“…8,10,[12][13][14][15]21,23,26,28,[32][33][34][35][36]38,[40][41][42][43][48][49][50][51][52][53][54]57,59,61 In five studies, 11,17,19,29,44 the authors acknowledged that owing to the retrospective nature of the study, it was not possible to analyze the point of menstrual cycle, although, following institutional protocol, screening breast MRI of patients who were pre-menopausal was performed during the second week of the menstrual cycle. In a total of 14 studies, the authors stated the menstrual period.…”

Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy

“…Such techniques, while potentially less reproducible, allow for user experience and interpretation to be taken into account and might go some way to obviate the issue of erroneous exclusion of viable tumour as a result of changed enhancement patterns in response to NAC. 23 The aim of this study was to investigate whether changes in ETV or FTV between baseline and interim MRI are useful in predicting a pCR in patients undergoing NAC for primary breast cancer. As ETV is a user-interactive technique, the reproducibility of ETV was also measured.…”